1. US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. 2010–2014.
https://seer.cancer.gov/csr/1975_2014/results_single/sect_a_table.03_2pgs.pdf
Accessed 18 Apr 2017.
2. National Comprehensive Cancer Network. Melanoma. (Version 1.2017)
https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf
Accessed 22 Apr 2017.
3. National Comprehensive Cancer Network. Kidney Cancer. In: Version 2; 2017.
https://www.nccn.org/professionals/physician_gls/pdf/kidney_blocks.pdf Accessed 22 Apr 2017
.
4. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Interventions (table 3). Oncology. 2002;13:14.
5. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J of Clin Onc. 1993;11(10):1969–77.